Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
L. Orsolini, C. Tomasetti, A. Valchera, R. Vecchiotti, I. Matarazzo, F. Vellante, F. Iasevoli, E. F. Buonaguro, M. Fornaro, A. L. C. Fiengo, G. Martinotti, M. Mazza, G. Perna, A. Carano, A. De Bartolomeis, M. Di Giannantonio & D. De Berardis. (2016) An update of safety of clinically used atypical antipsychotics. Expert Opinion on Drug Safety 15:10, pages 1329-1347.
Read now
Read now
Rachel Franklin, Sam Zorowitz, Andrew K Corse, Alik S Widge & Thilo Deckersbach. (2015) Lurasidone for the treatment of bipolar depression: an evidence-based review. Neuropsychiatric Disease and Treatment 11, pages 2143-2152.
Read now
Read now
Young Sup Woo, Hee Ryung Wang & Won-Myong Bahk. (2013) Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatric Disease and Treatment 9, pages 1521-1529.
Read now
Read now
Joshua T Kantrowitz & Leslie Citrome. (2012) Lurasidone for schizophrenia: what’s different?. Expert Review of Neurotherapeutics 12:3, pages 265-273.
Read now
Read now
Jose de Leon, Vincenza Santoro, Concetta D'Arrigo & Edoardo Spina. (2012) Interactions between antiepileptics and second-generation antipsychotics. Expert Opinion on Drug Metabolism & Toxicology 8:3, pages 311-334.
Read now
Read now
Leslie Citrome. (2011) Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatric Disease and Treatment 7, pages 325-339.
Read now
Read now
Chris M. Kozma, Terra Slaton, Riad Dirani, John Fastenau, Srihari Gopal & David Hough. (2011) Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE). Current Medical Research and Opinion 27:8, pages 1603-1611.
Read now
Read now
Articles from other publishers (28)
Mujeeb U. Shad. (2023) Seventy Years of Antipsychotic Development: A Critical Review. Biomedicines 11:1, pages 130.
Crossref
Crossref
Nicholas M. Barnes, Gerard P. Ahern, Carine Becamel, Joël Bockaert, Michael Camilleri, Severine Chaumont-Dubel, Sylvie Claeysen, Kathryn A. Cunningham, Kevin C. Fone, Michael Gershon, Giuseppe Di Giovanni, Nathalie M. Goodfellow, Adam L. Halberstadt, Rachel M. Hartley, Ghérici Hassaine, Katharine Herrick-Davis, Ruud Hovius, Enza Lacivita, Evelyn K. Lambe, Marcello Leopoldo, Finn Olav Levy, Sarah C. R. Lummis, Philippe Marin, Luc Maroteaux, Andrew C. McCreary, David L. Nelson, John F. Neumaier, Adrian Newman-Tancredi, Hugues Nury, Alexander Roberts, Bryan L. Roth, Anne Roumier, Gareth J. Sanger, Milt Teitler, Trevor Sharp, Carlos M. Villalón, Horst Vogel, Stephanie W. Watts & Daniel Hoyer. (2020) International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. Pharmacological Reviews 73:1, pages 310-520.
Crossref
Crossref
Marcin Siwek, Anna J. Krupa & Anna Wasik. (2020) Lurasidone – pharmacodynamic and pharmacokinetic properties, clinical potential and interaction risk. Pharmacotherapy in Psychiatry and Neurology 36:2, pages 117-134.
Crossref
Crossref
Mohammed Sawan, Tarek Nayfeh, Abdul M Majzoub, Homam Alabaji, Saria Alnahas, Tareq Al Saadi & Adib Essali. (2015) Iloperidone versus placebo for schizophrenia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Michelle A. Worthington & Rif S. El-Mallakh. (2015) A Naturalistic Retrospective Review of Weight Gain in Bipolar Patients Treated With Second Generation Antipsychotics. Journal of Clinical Psychopharmacology 35:2, pages 192-193.
Crossref
Crossref
Nicole Ganzer, Brandon Utter, Beth DeJongh, Michael Behrens, Guadalupe Garcia & Rebecca Graham. (2015) Re-implementation of a pharmacist-managed metabolic syndrome clinic in an outpatient mental health clinic setting. Mental Health Clinician 5:1, pages 57-62.
Crossref
Crossref
George Awad, Mariam Hassan, Antony Loebel, Jay Hsu, Andrei Pikalov & Krithika Rajagopalan. (2014) Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia. BMC Psychiatry 14:1.
Crossref
Crossref
Tom Parke, Vladimir Dragalin, Ibrahim Turkoz, Olga Marchenko & Virginia Haynes. (2014) Adaptive Design Applied to Identification of the Minimum Effective Dose in Schizophrenia. Therapeutic Innovation & Regulatory Science 48:1, pages 41-50.
Crossref
Crossref
Leslie Citrome. (2013) A Review of the Pharmacology, Efficacy and Tolerability of Recently Approved and Upcoming Oral Antipsychotics: An Evidence-Based Medicine Approach. CNS Drugs 27:11, pages 879-911.
Crossref
Crossref
Enza Lacivita, Paola De Giorgio, Daniela Patarnello, Mauro Niso, Nicola A. Colabufo, Francesco Berardi, Roberto Perrone, Grzegorz Satala, Beata Duszynska, Andrzej J. Bojarski & Marcello Leopoldo. (2013) Towards metabolically stable 5-HT7 receptor ligands: a study on 1-arylpiperazine derivatives and related isosters. Experimental Brain Research 230:4, pages 569-582.
Crossref
Crossref
Shijin Yin, Jialie Luo, Aihua Qian, Junhui Du, Qing Yang, Shentai Zhou, Weihua Yu, Guangwei Du, Richard B. Clark, Edgar T. Walters, Susan M. Carlton & Hongzhen Hu. (2013) Retinoids activate the irritant receptor TRPV1 and produce sensory hypersensitivity. Journal of Clinical Investigation 123:9, pages 3941-3951.
Crossref
Crossref
A. George Awad & Lakshmi N. P. Voruganti. (2013) The Impact of Newer Atypical Antipsychotics on Patient-Reported Outcomes in Schizophrenia. CNS Drugs 27:8, pages 625-636.
Crossref
Crossref
Melvin George, Radhika Amrutheshwar, Ravi Philip Rajkumar, Shivanand Kattimani & Steven Aibor Dkhar. (2013) Newer antipsychotics and upcoming molecules for schizophrenia. European Journal of Clinical Pharmacology 69:8, pages 1497-1509.
Crossref
Crossref
Lindsay N. Cates, Amanda J. Roberts, Salvador Huitron-Resendiz & Peter B. Hedlund. (2013) Effects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtype. Neuropharmacology 70, pages 211-217.
Crossref
Crossref
T. Scott Stroup, Matthew J. Byerly, Henry A. Nasrallah, Neepa Ray, Ahsan Y. Khan, J. Steven Lamberti, Ira D. Glick, Richard M. Steinbook, Joseph P. McEvoy & Robert M. Hamer. (2013) Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: Results from a randomized controlled trial. Schizophrenia Research 146:1-3, pages 190-195.
Crossref
Crossref
Herbert Y. Meltzer. (2013) Update on Typical and Atypical Antipsychotic Drugs. Annual Review of Medicine 64:1, pages 393-406.
Crossref
Crossref
Heidi N. Boyda, Ric M. Procyshyn, Catherine C. Y. Pang, Erin Hawkes, Daniel Wong, Chen Helen Jin, William G. Honer & Alasdair M. Barr. (2013) Metabolic Side-Effects of the Novel Second-Generation Antipsychotic Drugs Asenapine and Iloperidone: A Comparison with Olanzapine. PLoS ONE 8:1, pages e53459.
Crossref
Crossref
Leslie CitromeLeslie Citrome. 2013. Handbook of Treatment-resistant Schizophrenia. Handbook of Treatment-resistant Schizophrenia
37
56
.
Leslie CitromeLeslie Citrome. 2013. Handbook of Treatment-resistant Schizophrenia. Handbook of Treatment-resistant Schizophrenia
29
33
.
Dieter NaberMartin Lambert & Dieter Naber. 2012. Current Schizophrenia. Current Schizophrenia
5
67
.
Lisbeth Patteet, Manuel Morrens, Kristof E. Maudens, Peter Niemegeers, Bernard Sabbe & Hugo Neels. (2012) Therapeutic Drug Monitoring of Common Antipsychotics. Therapeutic Drug Monitoring 34:6, pages 629-651.
Crossref
Crossref
Marc De Hert, Weiping Yu, Johan Detraux, Kim Sweers, Ruud van Winkel & Christoph U. Correll. (2012) Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder. CNS Drugs 26:9, pages 733-759.
Crossref
Crossref
Amaia López de Torre, Unax Lertxundi, Rafael Hernández & Juan Medrano. (2012) Antipsychotic polypharmacy: a needle in a haystack?. General Hospital Psychiatry 34:4, pages 423-432.
Crossref
Crossref
W. Wolfgang Fleischhacker & Alex Hofer. 2012. Handbuch der Psychopharmakotherapie. Handbuch der Psychopharmakotherapie
937
960
.
Marsal Sanches & Jair C. Soares. (2011) New Drugs for Bipolar Disorder. Current Psychiatry Reports 13:6, pages 513-521.
Crossref
Crossref
Norman L. Keltner, Randy L. Moore & Joan S. Grant. (2011) Biological Perspectives: Update on Newer Antipsychotic Drugs: Are They Evidence Based?. Perspectives in Psychiatric Care 47:4, pages 220-226.
Crossref
Crossref
Leslie Citrome. (2011) Treatment-refractory schizophrenia: what is it and what has been done about it?. Neuropsychiatry 1:4, pages 325-347.
Crossref
Crossref
Young Sup WooWon-Myong Bahk. (2011) Recent advances in the pharmacotherapy of psychiatric disorders. Journal of the Korean Medical Association 54:10, pages 1061.
Crossref
Crossref